CR9202A - Macrolidos - Google Patents

Macrolidos

Info

Publication number
CR9202A
CR9202A CR9202A CR9202A CR9202A CR 9202 A CR9202 A CR 9202A CR 9202 A CR9202 A CR 9202A CR 9202 A CR9202 A CR 9202A CR 9202 A CR9202 A CR 9202A
Authority
CR
Costa Rica
Prior art keywords
compounds
methods
macrolidos
intermediates
antibacterial
Prior art date
Application number
CR9202A
Other languages
English (en)
Inventor
Stanley Chupak Louis
Edgard Flanagan Mark
Kaneko Takushi
Victor Magee Thomas
Carl Noe Mark
Reilly Usa
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35809765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9202(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CR9202A publication Critical patent/CR9202A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Tires In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos macrolidos per se, como se muestran a continuacion y se definen en esta memoria, y su uso, p. ej., como agentes antibacterianos y antiprotozoarios en animales, incluyendo seres humanos: Tambien se describen metodos para preparar los compuestos, productos intermedios y sus composiciones farmaceuticas, y metodos para tratar o prevenir la enfermedad por administracion de los compuestos a los sujetos que lo necesiten. Este resumen es solo un extracto y no limita la invencion.
CR9202A 2004-12-21 2007-06-21 Macrolidos CR9202A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63809704P 2004-12-21 2004-12-21
US71753005P 2005-09-14 2005-09-14

Publications (1)

Publication Number Publication Date
CR9202A true CR9202A (es) 2007-07-16

Family

ID=35809765

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9202A CR9202A (es) 2004-12-21 2007-06-21 Macrolidos

Country Status (35)

Country Link
US (1) US7462600B2 (es)
EP (2) EP1836211B1 (es)
JP (1) JP4111994B1 (es)
KR (1) KR100897678B1 (es)
CN (1) CN101120011A (es)
AP (1) AP2007004026A0 (es)
AR (1) AR052824A1 (es)
AT (1) ATE459633T1 (es)
AU (1) AU2005317735B2 (es)
BR (1) BRPI0519135A2 (es)
CA (1) CA2591746A1 (es)
CR (1) CR9202A (es)
DE (1) DE602005019786D1 (es)
DK (1) DK1836211T3 (es)
EA (1) EA011281B1 (es)
ES (1) ES2339871T3 (es)
GE (1) GEP20094834B (es)
GT (1) GT200500378A (es)
HN (1) HN2005036113A (es)
HR (1) HRP20100253T1 (es)
IL (1) IL183661A0 (es)
MA (1) MA29108B1 (es)
MX (1) MX2007007598A (es)
NL (1) NL1030713C2 (es)
NO (1) NO20073367L (es)
PE (1) PE20060948A1 (es)
PL (1) PL1836211T3 (es)
PT (1) PT1836211E (es)
SI (1) SI1836211T1 (es)
TN (1) TNSN07233A1 (es)
TW (1) TW200626608A (es)
UA (1) UA85937C2 (es)
UY (1) UY29285A1 (es)
WO (1) WO2006067589A1 (es)
ZA (1) ZA200705108B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367669B2 (en) * 2005-06-15 2013-02-05 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
US9133212B1 (en) 2005-06-15 2015-09-15 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
EP3290427A1 (en) 2005-08-24 2018-03-07 Melinta Therapeutics, Inc. Triazole compounds and methods of making and using the same
AP2009004985A0 (en) * 2007-03-13 2009-10-31 Pfizer Prod Inc Erythromycin-based macrolides
EP2136806A4 (en) * 2007-03-21 2011-11-23 Creative Antibiotics Sweden Ab METHOD AND MEANS FOR PREVENTING AND SUPPRESSING TYPE III SECRETION IN INFECTIONS BY GRAM-NEGATIVE BACTERIA
US20110040078A1 (en) * 2007-10-25 2011-02-17 Siegfried Wolf Process for the production of telithromycin
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
WO2009080534A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
ES2582794T3 (es) 2009-08-13 2016-09-15 Basilea Pharmaceutica Ag Nuevos macrólidos y su uso
MX361413B (es) * 2010-03-22 2018-12-05 Cempra Pharmaceuticals Inc Star Formas cristalinas de un macrólido y usos para las mismas.
EP2696873B1 (en) 2011-04-12 2022-08-03 The United States of America, as represented by The Secretary, Department of Health and Human Services Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
CN102558047B (zh) * 2011-12-14 2013-10-30 天津药物研究院药业有限责任公司 3-甲基喹啉的制备方法
NZ700182A (en) 2012-03-27 2017-02-24 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
BR112015000649A2 (pt) 2012-07-13 2017-06-27 Hoffmann La Roche compostos, composição farmacêutica, uso de um composto, método para tratar ou melhorar câncer e invenção
KR101663864B1 (ko) * 2013-04-19 2016-10-07 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 약학조성물
TW201534586A (zh) 2013-06-11 2015-09-16 Orion Corp 新穎ｃｙｐ１７抑制劑／抗雄激素劑
CN103739643A (zh) * 2013-12-30 2014-04-23 华东理工大学 利用分子印迹技术对红霉素进行回收分离纯化的方法
CN104230891B (zh) * 2014-08-27 2016-03-30 于宗光 一种托匹司他的制备方法
WO2018067663A2 (en) * 2016-10-04 2018-04-12 Biopharmati Sa Ketolides having antibacterial activity
AU2020286381C1 (en) 2019-06-04 2025-07-10 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists
AU2020288559C1 (en) * 2019-06-04 2025-07-24 Hager Biosciences, Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
CN111793022A (zh) * 2020-04-27 2020-10-20 滁州拜奥生物科技有限公司 一种3-甲基喹啉的制备方法
US20260070922A1 (en) * 2022-09-01 2026-03-12 Hager Biosciences, Llc Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators composition, methods for treating neurological and psychiatric disorders

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2653899A (en) 1952-04-14 1953-09-29 Lilly Co Eli Erythromycin, its salts, and method of preparation
US2823203A (en) 1954-06-24 1958-02-11 Abbott Lab Method of producing substantially pure erythromycin a
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
SI8110592A8 (en) 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
US5075289A (en) 1988-06-07 1991-12-24 Abbott Laboratories 9-r-azacyclic erythromycin antibiotics
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5523399A (en) 1991-12-27 1996-06-04 Taisho Pharmaceutical Co., Ltd. 5-O-desosaminylerythronolide derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
FR2727969B1 (fr) 1994-12-09 1997-01-17 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5747466A (en) 1995-11-08 1998-05-05 Abbott Laboratories 3-deoxy-3-descladinose derivatives of erythromycins A and B
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
JP2000509712A (ja) 1996-05-07 2000-08-02 アボツト・ラボラトリーズ ６―ｏ―置換エリスロマイシン及びその製造方法
US5750510A (en) 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
FR2748746B1 (fr) 1996-05-14 1998-08-14 Hoechst Marion Roussel Inc Nouveau procede d'isomerisation du radical methyle en 10 de derives de l'erythromycine
US6271255B1 (en) 1996-07-05 2001-08-07 Biotica Technology Limited Erythromycins and process for their preparation
FR2751656B1 (fr) 1996-07-24 1998-10-16 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
DE69733422T2 (de) 1996-09-04 2006-05-04 Abbott Laboratories, Abbott Park 6-0-substituierte ketoliden mit antibakteriellen wirkung
US5804565A (en) 1996-09-24 1998-09-08 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
US6191118B1 (en) * 1996-11-27 2001-02-20 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
US6140479A (en) 1997-03-24 2000-10-31 Taisho Pharmaceuticals Co., Ltd. Erythromycin a derivatives
WO1998051696A1 (en) 1997-05-09 1998-11-19 Pfizer Products Inc. Erythromycin derivatives
US20020025937A1 (en) 2000-03-20 2002-02-28 Yong-Jin Wu 9-oxime erythromycin derivatives
EP0895999A1 (en) 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics
ZA987689B (en) 1997-09-02 1999-02-24 Abbott Lab 3-descladinose 6-O substituted erythromycin derivatives
US6034069A (en) 1997-09-30 2000-03-07 Abbott Laboratories 3-'N-modified 6-O-substituted erythromycin ketolide derivatives having antibacterial activity
PA8461401A1 (es) 1997-10-29 2000-05-24 Pfizer Prod Inc Derivados de eritromicina triciclicos
AU9649598A (en) 1997-10-29 1999-05-17 Taisho Pharmaceutical Co., Ltd. Erythromycin a, 11,12-carbamate derivatives
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
AP9801420A0 (en) 1998-01-02 1998-12-31 Pfizer Prod Inc Novel macrolides.
ATE275151T1 (de) 1998-03-03 2004-09-15 Pfizer Prod Inc 3,6-ketal-makrolidantibiotika
US5955440A (en) 1998-03-27 1999-09-21 Abbott Laboratories Macrolide LHRH antagonists
US6248719B1 (en) 1998-06-03 2001-06-19 Pfizer Inc Tricyclic 3-keto derivatives of 6-O-methylerthromycin
JP4573925B2 (ja) 1998-07-09 2010-11-04 アベンティス・ファーマ・ソシエテ・アノニム 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
TR200101241T2 (tr) 1998-11-03 2001-09-21 Pfizer Products Inc. Yeni makrolit antibiyotikler
US6262030B1 (en) 1998-11-03 2001-07-17 Pfizer Inc. Erythromycin derivatives
DE69933897T2 (de) 1998-12-10 2007-03-15 Pfizer Products Inc., Groton Carbamat- und Carbazatketolid-Antibiotika
CA2359708C (en) 1999-01-27 2005-10-25 Pfizer Products Inc. Ketolide antibiotics
US6054435A (en) 1999-03-19 2000-04-25 Abbott Laboratories 6-O-substituted macrolides having antibacterial activity
CA2370743A1 (en) * 1999-04-16 2000-10-26 Dennis Hlasta Ketolide antibacterials
ATE340183T1 (de) 1999-04-16 2006-10-15 Kosan Biosciences Inc Antiinfektiöse makrolidderivate
US6939861B2 (en) 1999-04-16 2005-09-06 Kosan Biosciences, Inc. Amido macrolides
US20020061857A1 (en) 1999-04-23 2002-05-23 Yong-Jin Wu 9-amino-3-oxo erythromycin derivatives
US20020077302A1 (en) 1999-04-23 2002-06-20 Yong-Jin Wu Tricyclic erythromycin derivatives
US6355620B1 (en) 1999-05-14 2002-03-12 Abbott Laboratories C-2 modified erythromycin derivatives
HUP0201516A3 (en) 1999-05-24 2003-03-28 Pfizer Prod Inc 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
JP2001072669A (ja) 1999-09-07 2001-03-21 Showa Kako Kk ７−クロロ−２，４（１ｈ，３ｈ）−キナゾリンジオンの製造方法
US6569836B2 (en) 1999-12-02 2003-05-27 Abbott Laboratories 6-O-alkyl-2-nor-2-substituted ketolide derivatives
EP1114826A3 (en) 1999-12-29 2001-10-31 Pfizer Products Inc. Novel antibacterial and prokinetic macrolides
EP1122261A3 (en) 2000-01-31 2001-09-26 Pfizer Products Inc. 13 and 14-membered antibacterial macrolides
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
EP1146051A3 (en) 2000-04-10 2001-10-31 Pfizer Products Inc. Erythromycin A derivatives
US20020061856A1 (en) 2000-04-24 2002-05-23 Yong-Jin Wu Novel tricyclic erythromycin derivatives
EP1167376B1 (en) 2000-06-30 2004-07-14 Pfizer Products Inc. Macrolide antibiotics
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
US20040077557A1 (en) 2000-12-21 2004-04-22 Sulejman Ali Macrolide antibiotics
US20020132782A1 (en) 2001-01-18 2002-09-19 Zhenkun Ma 9-amino erythromycin derivatives with antibacterial activity
CA2451391A1 (en) 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
WO2005070918A1 (en) 2002-05-13 2005-08-04 Enanta Pharmaceuticals, Inc. Process for the preparation of t-11 bicyclic erythromycin derivatives
US7064110B2 (en) 2002-05-13 2006-06-20 Enanta Pharmaceuticals, Inc. 6-11 bicycle ketolide derivatives
KR20060005378A (ko) 2003-04-21 2006-01-17 다이이찌 세이야꾸 가부시기가이샤 ５원 복소환 유도체
US20080287376A1 (en) 2004-07-28 2008-11-20 Mohammad Salman Ketolide Derivatives as Antibacterial Agents
US20090170790A1 (en) 2004-10-25 2009-07-02 Biswajit Das Ketolide derivatives as antibacterial agents
GB0424951D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
US7419962B2 (en) 2004-12-07 2008-09-02 Enanta Pharmaceuticals, Inc. 3,6-bicyclolides
WO2006065721A2 (en) 2004-12-13 2006-06-22 Enanta Pharmaceuticals, Inc. 11, 12-lactone bicyclolides
WO2006065743A2 (en) 2004-12-13 2006-06-22 Enanta Pharmaceuticals, Inc. Tetracylic bicyclolides

Also Published As

Publication number Publication date
GT200500378A (es) 2006-11-28
JP4111994B1 (ja) 2008-07-02
PL1836211T3 (pl) 2010-07-30
TW200626608A (en) 2006-08-01
SI1836211T1 (sl) 2010-04-30
IL183661A0 (en) 2007-09-20
EP1836211B1 (en) 2010-03-03
EA200701113A1 (ru) 2007-12-28
UA85937C2 (uk) 2009-03-10
CA2591746A1 (en) 2006-06-29
HRP20100253T1 (hr) 2010-06-30
EA011281B1 (ru) 2009-02-27
EP1836211A1 (en) 2007-09-26
CN101120011A (zh) 2008-02-06
HN2005036113A (es) 2010-12-06
EP2233493A1 (en) 2010-09-29
PE20060948A1 (es) 2006-10-11
TNSN07233A1 (fr) 2008-11-21
UY29285A1 (es) 2006-07-31
AU2005317735A1 (en) 2006-06-29
BRPI0519135A2 (pt) 2008-12-23
NO20073367L (no) 2007-09-05
MA29108B1 (fr) 2007-12-03
ZA200705108B (en) 2009-01-28
AR052824A1 (es) 2007-04-04
ATE459633T1 (de) 2010-03-15
DK1836211T3 (da) 2010-05-17
NL1030713C2 (nl) 2006-12-12
AU2005317735B2 (en) 2009-06-04
MX2007007598A (es) 2007-07-25
JP2008524319A (ja) 2008-07-10
KR100897678B1 (ko) 2009-05-14
US7462600B2 (en) 2008-12-09
US20060135447A1 (en) 2006-06-22
ES2339871T3 (es) 2010-05-26
KR20070089191A (ko) 2007-08-30
WO2006067589A1 (en) 2006-06-29
GEP20094834B (en) 2009-11-25
DE602005019786D1 (de) 2010-04-15
NL1030713A1 (nl) 2006-06-22
AP2007004026A0 (en) 2007-06-30
PT1836211E (pt) 2010-04-08

Similar Documents

Publication Publication Date Title
CR9202A (es) Macrolidos
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
HN2011001593A (es) Piridiloxi-indoles del vegf-r2 y uso de los mismos para el tratmiento de enfermedades
PA8595901A1 (es) "n-arilheterociclos sustituidos, procedimientos para su preparacion, y su empleo como medicamentos
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
PA8553001A1 (es) Compuestos biciclicos aromaticos sustituidos con amino-alquilo, procedimiento para su preparacion y su utilizacion como medicamentos.
UY31539A1 (es) Agentes antelminticos y su uso
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
PA8570901A1 (es) Derivados de acil-4-carboxifenilurea, procedimientos para su preparacion y su uso
BRPI0413558A (pt) compostos contendo imidazo substituìdo por hidroxilamina
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
ECSP088225A (es) 1h-imidazopiridinas sustituidas con hidroxi y procedimientos
HN2000000041A (es) Compuestos para tratar la obesidad
AR035284A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
CU20090058A7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
UY31457A1 (es) Derivados acidos de cicloalquilamino
PA8599401A1 (es) Nueva difenilazetidinona con propiedades fisiologicas mejoradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
GT200900031A (es) Aplicacion por via transdermica de triazinas para combatir infecciones por coccidios
BRPI0507801A (pt) compostos de azetidina substituìda, processo para a preparação de compostos de azetidina substituìda, medicamento e uso de pelo menos um composto de azetidina substituìda
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
CR11406A (es) Conjugados de neurturina novedosos para uso farmaceutico
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
HN2003000104A (es) Derivados de ciclopenteno
UY29417A1 (es) Agentes endoparasiticidas
PA8596701A1 (es) Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)